PDS Biotechnology (PDSB) Azione Prezzo
PDS Biotechnology Prezzo
Il target di prezzo di consenso a 12 mesi per PDS Biotechnology è 4,59 USD, circa il 268,7% sopra il prezzo attuale di mercato. Su 9 analisti, 8 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
PDS Biotechnology Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
PDS Biotechnology Azione e analisi azionaria
Domande frequenti sull'azione PDS Biotechnology
The business model of PDS Biotechnology Corp focuses on developing and commercializing novel immunotherapies for the treatment of various types of cancer. By leveraging its proprietary Versamune® platform, PDS Biotechnology aims to stimulate the immune system, enhancing its ability to recognize and destroy tumors. This innovative approach combines immunotherapy with precision medicine to deliver more effective and individualized cancer treatments. PDS Biotechnology's dedication to advancing immunotherapies positions them as a key player in the biotechnology industry, contributing to the development of potentially life-saving treatments for cancer patients.
PDS Biotechnology Corp is primarily active in the biotechnology industry.
Some of the main competitors of PDS Biotechnology Corp in the market include companies like Merck & Co., Inc., Bristol-Myers Squibb Company, and AstraZeneca PLC.
PDS Biotechnology Corp is a leading biotechnology company specializing in developing and commercializing novel immunotherapies for cancer and infectious diseases. Founded in 2005, the company has focused on its proprietary Versamune® platform technology, which activates the immune system for an effective response against various diseases. PDS Biotechnology Corp has conducted extensive research and clinical trials to demonstrate the potential of its platform in treating HPV-associated cancers, including cervical, head, and neck cancers. With its innovative approach and promising pipeline, PDS Biotechnology Corp is committed to advancing immunotherapies that have the potential to revolutionize the treatment landscape for patients worldwide.
PDS Biotechnology Corp has achieved significant milestones in its journey. The company has successfully developed Versamune®, a proprietary clinical-stage immunotherapy platform, which has shown promising results in preclinical and early clinical studies. PDS Biotechnology Corp has also made progress in its partnership with the National Cancer Institute (NCI) to advance cancer vaccines using its Versamune® platform. Additionally, the company has garnered attention for its involvement in the fight against HPV-associated cancers, including the initiation of a Phase 2 clinical trial for its lead candidate, PDS0101. Overall, PDS Biotechnology Corp continues to make important strides in developing innovative immunotherapies to address major medical challenges.
PDS Biotechnology Corp is primarily present in the United States.
PDS Biotechnology Corp represents a commitment to advancing healthcare through innovative biotechnological solutions. The company's corporate philosophy revolves around developing novel immunotherapies to effectively treat various types of cancer and infectious diseases. PDS Biotechnology Corp focuses on leveraging its proprietary Versamune® platform to create targeted therapies that enhance the immune system's ability to combat disease. This approach aligns with their ultimate goal of improving patient outcomes and quality of life. With a strong emphasis on research, clinical development, and collaboration with key industry stakeholders, PDS Biotechnology Corp strives to make a significant impact on the future of immunotherapy.
9 analisti valutano attualmente l’azione PDS Biotechnology: 8 raccomandano l’acquisto, 1 la tenuta e 0 la vendita.
Convertita al tasso di cambio attuale, l’azione PDS Biotechnology quota 1,12 EUR (1,25 USD).
L’azione PDS Biotechnology (PDSB) è quotata su 4 borse, tra cui: NASDAQ (PDSB), Frankfurt (EU6.F), München (EU6.MU), Düsseldorf (EU6.DU).
PDS Biotechnology Corp is a biopharmaceutical company specializing in the research and development of immunotherapeutic cancer treatments. The company utilizes a proprietary platform technology called Versamune® for the development of immunotherapeutics for treating various types of cancer. The business model of PDS Biotechnology Corp consists of two main divisions: research and product development, and strategic partnerships. The company's research and product development division focuses on developing immunotherapeutics based on Versamune®. This platform technology consists of a proprietary combination of molecules that activate the immune system and program it to specifically recognize and destroy cancer cells. The main product of PDS Biotechnology Corp currently is an immunotherapeutic called PDS0101, which was developed based on Versamune® and the PD-1 antigen. PDS0101 is currently in Phase 2 clinical development and is being tested for the treatment of HPV-associated cancer. The company also has other immunotherapeutics in the pipeline that have been developed based on Versamune® and could be used for the treatment of breast cancer, lung cancer, and other types of cancer. PDS Biotechnology Corp's strategic partnerships focus on collaborating with other companies and institutions to enhance access to resources and expertise. For example, the company is currently working with the National Cancer Institute to test its immunotherapeutics in clinical trials. In another collaboration, PDS Biotechnology Corp has entered into a partnership agreement with Farmacore Biotechnologia to develop and market its immunotherapeutics in Brazil and other Latin American countries. The business model of PDS Biotechnology Corp has the advantage of operating in a rapidly growing market. Immunotherapy has gained significant importance in recent years and offers a promising new approach to cancer treatment. This market is expected to continue growing in the coming years as more companies and research institutions invest in the development of immunotherapeutics. The company is also operating in a market segment that is traditionally dominated by large pharmaceutical companies. Most of the major pharmaceutical companies are currently investing substantial resources in immunotherapy development, creating intense competition. However, smaller companies like PDS Biotechnology Corp have the opportunity to focus on more specific indications and respond quickly to changes in market demand, as many of the large pharmaceutical companies are limited in the number of product candidates they can focus on. In summary, the business model of PDS Biotechnology Corp aims to develop innovative immunotherapeutics for cancer treatment while also building partnerships to improve access to resources and expertise. With its proprietary Versamune® platform technology and increasing presence in Latin America, the company has good growth prospects in a rapidly evolving market.
Il fatturato non può essere attualmente calcolato per PDS Biotechnology.
Il attesa profitto di PDS Biotechnology ammonta a -25,66 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di PDS Biotechnology è attualmente -2,25. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione PDS Biotechnology.
L'indicatore Price-to-Sales (P/S) per PDS Biotechnology non può essere calcolato al momento.
Il Quality Score AlleAktien per PDS Biotechnology è 2/10.
L'ISIN di PDS Biotechnology è US70465T1079. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di PDS Biotechnology è A2PF3F. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di PDS Biotechnology è PDSB. Con questo simbolo di borsa vengono negoziate le azioni PDS Biotechnology in borsa.
Azione PDS Biotechnology
Gruppo di pari di PDS Biotechnology
PDS Biotechnology Ticker
PDS Biotechnology FIGI
Altre metriche e analisi di PDS Biotechnology in Deep Dive.
La nostra analisi azionaria dell'azione PDS Biotechnology include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di PDS Biotechnology. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: